Technical Analysis for ARDS - Aridis Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade D 9.65 -1.33% -0.13
ARDS closed down 1.33 percent on Thursday, April 18, 2019, on 16 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Flat Down
See historical ARDS trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish -1.33%
Narrow Range Bar Range Contraction -1.33%
Oversold Stochastic Weakness -1.33%
Stochastic Reached Oversold Weakness -2.00%

Older signals for ARDS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.
Medicine Biopharmaceutical Medical Specialties Infectious Diseases Immunotherapy Antibodies Monoclonal Antibody Bacterial Infections Infections Healthcare Associated Infections Bacterial Diseases Pneumonia Pathogenic Bacteria Pseudomonas Aeruginosa Targeted Immunotherapy
Is ARDS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.85
52 Week Low 7.59
Average Volume 5,043
200-Day Moving Average 0.0
50-Day Moving Average 9.6556
20-Day Moving Average 10.6404
10-Day Moving Average 10.3214
Average True Range 0.7663
ADX 27.53
+DI 21.9017
-DI 18.6828
Chandelier Exit (Long, 3 ATRs ) 10.1011
Chandelier Exit (Short, 3 ATRs ) 11.849
Upper Bollinger Band 11.8195
Lower Bollinger Band 9.4613
Percent B (%b) 0.08
BandWidth 22.162701
MACD Line 0.0233
MACD Signal Line 0.2179
MACD Histogram -0.1946
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.65
Resistance 3 (R3) 9.65 9.65 9.65
Resistance 2 (R2) 9.65 9.65 9.65 9.65
Resistance 1 (R1) 9.65 9.65 9.65 9.65 9.65
Pivot Point 9.65 9.65 9.65 9.65 9.65
Support 1 (S1) 9.65 9.65 9.65 9.65 9.65
Support 2 (S2) 9.65 9.65 9.65 9.65
Support 3 (S3) 9.65 9.65 9.65
Support 4 (S4) 9.65